Cns Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.468
- Today's High:
- $1.5307
- Open Price:
- $1.53
- 52W Low:
- $0.611
- 52W High:
- $11.304
- Prev. Close:
- $1.45
- Volume:
- 11425
Company Statistics
- Market Cap.:
- $9.82 million
- Book Value:
- 1.568
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -91.49%
- Return on Equity TTM:
- -186.44%
Company Profile
Cns Pharmaceuticals Inc had its IPO on 2019-11-08 under the ticker symbol CNSP.
The company operates in the Healthcare sector and Biotechnology industry. Cns Pharmaceuticals Inc has a staff strength of 3 employees.
Stock update
Shares of Cns Pharmaceuticals Inc opened at $1.53 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.47 - $1.53, and closed at $1.47.
This is a +1.38% increase from the previous day's closing price.
A total volume of 11,425 shares were traded at the close of the day’s session.
In the last one week, shares of Cns Pharmaceuticals Inc have slipped by -13.02%.
Cns Pharmaceuticals Inc's Key Ratios
Cns Pharmaceuticals Inc has a market cap of $9.82 million, indicating a price to book ratio of 0.4006 and a price to sales ratio of 0.
In the last 12-months Cns Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-17034746. The EBITDA ratio measures Cns Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cns Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -91.49% with a return of equity of -186.44%.
In Q1, Cns Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cns Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-15.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cns Pharmaceuticals Inc’s profitability.
Cns Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.289. Its price to sales ratio in the trailing 12-months stood at 0.
Cns Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $7.41 million
- Total Liabilities
- $3.92 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Cns Pharmaceuticals Inc ended 2024 with $7.41 million in total assets and $0 in total liabilities. Its intangible assets were valued at $7.41 million while shareholder equity stood at $3.49 million.
Cns Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $3.92 million in other current liabilities, 2226.00 in common stock, $-55647624.00 in retained earnings and $0 in goodwill. Its cash balance stood at $5.11 million and cash and short-term investments were $5.11 million. The company’s total short-term debt was $289,075 while long-term debt stood at $0.
Cns Pharmaceuticals Inc’s total current assets stands at $6.97 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.78 million and inventory worth $0.
In 2024, Cns Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Cns Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.47
- 52-Week High
- $11.304
- 52-Week Low
- $0.611
- Analyst Target Price
- $10
Cns Pharmaceuticals Inc stock is currently trading at $1.47 per share. It touched a 52-week high of $11.304 and a 52-week low of $11.304. Analysts tracking the stock have a 12-month average target price of $10.
Its 50-day moving average was $1.96 and 200-day moving average was $2.01 The short ratio stood at 0.02 indicating a short percent outstanding of 0%.
Around 1423.3% of the company’s stock are held by insiders while 626% are held by institutions.
Frequently Asked Questions About Cns Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.